<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00861549</url>
  </required_header>
  <id_info>
    <org_study_id>PH-CP005</org_study_id>
    <nct_id>NCT00861549</nct_id>
    <nct_alias>NCT00766428</nct_alias>
    <nct_alias>NCT00926679</nct_alias>
  </id_info>
  <brief_title>Bioavailability, Pharmacokinetics and Safety Evaluation of Phencynonate Hydrochloride in Healthy Volunteers</brief_title>
  <official_title>Bioavailability, Pharmacokinetics and Safety Evaluation of Phencynonate Hydrochloride in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PhytoHealth Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PhytoHealth Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the bioavailability of two formulations (Taiwan and
      China mainland) of phencynonate hydrochloride tablets and to generate pharmacokinetic and
      safety profiles of phencynonate hydrochloride in healthy volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PK parameters(1)Cmax,Tmax,Elimination half-life,AUC,Vd/F,Clt/F,MRT,relative BA and percentage of protein binding of plasma PCNH and its metabolite (2) D∞(u)and Clr of urine PCNH and its metabolite</measure>
    <time_frame>5 or 10 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety Variables:AE/lab. exam./PE/Vital signs/ECG</measure>
    <time_frame>5 to 10 days</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1mg / 0.5 tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2mg / 1 tablet; crossover with Phencynonate hydrochloride (2mg/1 tablet) made in China</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4mg / 2 tablets</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phencynonate hydrochloride</intervention_name>
    <description>2mg/tablet</description>
    <arm_group_label>cohort 1</arm_group_label>
    <arm_group_label>cohort 2</arm_group_label>
    <arm_group_label>cohort 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects must have signed and dated informed consent form.

          2. Subjects must be ≧ 18 and ≦ 40 years old, healthy, non-smoking male.

          3. Subjects with body weight within ± 20% ideal body weight

          4. Subjects with urinalysis data within acceptable range, including pH, blood, glucose
             and protein

          5. Subjects with laboratory evaluations data within acceptable range, including serum
             chemistry examinations (glucose, total cholesterol, TG, SGOT, SGPT, GSP, alkaline
             phosphatase, total bilirubin, total protein, albumin, r-GT, BUN, creatinine, uric
             acid) and hematology (complete blood count and platelets)

          6. Subjects with acceptable ECG and chest x-ray

        Exclusion Criteria:

          1. Subjects had taken any drugs within 14 days prior to screening.

          2. Subjects with history of glaucoma

          3. Subjects with history of ileus

          4. Subjects with history of benign prostate hypertrophy with urine retention

          5. Subjects with history of myasthenia gravis

          6. Subjects with history of asthma

          7. Subject with history of any other medical conditions that, in the opinion of the
             investigator, compromised subject safety or ability to comply with study procedures

          8. Subjects with history of drug or alcohol addiction or abuse within 1 year prior to
             screening

          9. Subjects with hypersensitivity to phencynonate hydrochloride or other drugs with
             similar chemical structure

         10. Subjects had donated blood more than 250 mL within the pervious 3 months prior to
             study

         11. Subjects had received any investigational drugs within 1 month prior to screening
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yaoh S Lin, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yaoh-Shiang Lin</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>General Clinical Research Center for New Drug Trial, Tri-Service General Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>114</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>September 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 10, 2009</study_first_submitted>
  <study_first_submitted_qc>March 12, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 13, 2009</study_first_posted>
  <last_update_submitted>September 13, 2011</last_update_submitted>
  <last_update_submitted_qc>September 13, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 14, 2011</last_update_posted>
  <responsible_party>
    <name_title>PhytoHealth Corporation</name_title>
    <organization>PhytoHealth Corporation</organization>
  </responsible_party>
  <keyword>Bioavailability</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Safety Evaluation</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

